- Market Intelligence
- Enterprise Platform
- News Data Feeds API
- Executive Briefings
- About Us
- Contact Us
- Case Studies
- Data Sheets
The healthcare sector has a well-earned reputation for ultra-pricey acquisitions. In 2017, for example, Gilead Sciences paid nearly $12 billion for Kite Pharma and its commercially unproven cell therapy platform. Kicking off this year, Bristol-Myers Squibb struck a $74 billion deal to acquire biotech heavyweight Celgene.
01.10.2012 10:35 Hamburg, Germany: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Hamburg, Germany, 04 August 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
ABOUT ENDOMETRIOSIS Endometriosis affects an estimated 176 million women worldwide or 10% of women of reproductive age. It is caused by the abnormal growth of tissue similar to that which lines the uterus (endometrial tissue) in locations outside of the uterine cavity, where it causes ectopic lesion growth and debilitating pain.
The FDA has approved Merck's (NYSE:MRK) Keytruda (pembrolizumab) for the adjuvant treatment of melanoma patients with lymph node involvement following complete resection, its 17th U.S. indication.
Job Attributes Job ID 1993 Location Shirley, NY Category Manufacturing/Production/Operations Department Production Overhead Business Unit NY Process Supervisor of Manufacturing, 3:00pm - 11:30pm Apply NEW SEARCH In Shirley, NY Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, is dedicated to the development and marketing of innovative, quality drugs for healthcare professionals, clinics, and hospitals across the United States and Canada.
Gilead Sciences, Inc. and its cell therapy subsidiary Kite have entered into a definitive agreement to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy. Under the terms of the agreement, Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2 percent of shares of Cell Design Labs that are currently held by Kite, for up to approximately $567 million.
Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis’ Exelon Patch. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer’s disease and the treatment of mild to moderate dementia associated with Parkinson’s disease.
After marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into the crowded market with two new meds. The drugmaker scored FDA approvals for a new non-nucleoside reverse transcriptase inhibitor called doravirine, both alone and in a combo with other HIV therapies.
Press Releases Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen Study will Evaluate Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), in Combination with Plexxikon’s PLX3397 Berkeley, CA, and Kenilworth, N.J.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2018-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada . The milestone payment is associated with the companies’ collaboration for a non-complement cardiovascular target with a large market opportunity.
The Karnataka High Court on Friday declined to quash criminal proceedings against Sanofi India Ltd., a pharmaceutical company, by the Central Bureau of Investigation (CBI) for allegedly cheating the Bhabha Atomic Research Centre (BARC), Mysuru, of ₹3.53 lakh during 2012-15 by conspiring with a scientific officer of the BARC.
IN: Catalent Inc. to Expand in Bloomington, Create Up to 200 New Jobs 15 Feb, 2019 The state of Indiana and the city of Bloomington announced that Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has commenced a significant expansion of its biologics manufacturing operations in Bloomington, with plans to create up to 200 new jobs by the end of 2024.
Pfizer entered into an agreement with the University of Szeged in Hungary that will allow the university's patients to be able to access the most modern therapies, reported the Budapest Business Journal. According to the news source, the university achieved clinical trial center certification under the "Pfizer Inspire" program in October 2018, becoming a part of the company's special network.
TARRYTOWN, N.Y. , Feb. 15, 2019 /PRNewswire/ -- Today the European Patent Office invalidated Immunex's European patent claiming antibodies that target human IL-4 receptors (IL-4R) Decision follows yesterday's ruling by the U.S. Patent & Trademark Office invalidating a similar Immunex patent claiming antibodies that target human IL-4R Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. , Feb. 14, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Cowen 39th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 11, 2019 . The session may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.
news C3i Solutions and Pfizer Consumer Health Named as Finalists in the 13th Stevie Awards for Sales & Customer Service C3i Solutions and Pfizer Consumer Health were named Finalists the Customer Service Outsourcing Provider of the Year category in the 13th annual Stevie® Awards for Sales & Customer Service.
Bayer said Friday that it has exercised its option to obtain full licensing rights for Vitrakvi (larotrectinib) and BAY 2731954, previously known as LOXO-195, which are being developed to treat adult and paediatric patients with advanced solid tumours harbouring NTRK gene fusions.
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) in Combination with Inlyta (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
HIMSS Analytics unveils new benchmarking model at HIMSS19. HIMSS Analytics has announced at HIMSS19 in Orlando that it is introducing the Digital Imaging Adoption Model for Enterprise Imaging - an eight-stage model aiming to help experts benchmark the use of IT in medical imaging.
Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents / Bayer to be solely responsible for the global development and commercialization of both larotrectinib and BAY 2731954 (LOXO-195) / Co-Promotion in the U.S.